|
Combination Therapy of Severe Aplastic Anemia Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Therapy of Severe Aplastic Anemia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Therapy of Severe Aplastic Anemia Clinical research trials and Combination Therapy of Severe Aplastic Anemia medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Therapy of Severe Aplastic Anemia. Combination Therapy of Severe Aplastic Anemia Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Therapy of Severe Aplastic Anemia clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Therapy of Severe Aplastic Anemia condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Therapy of Severe Aplastic Anemia  Combination Therapy of Severe Aplastic Anemia
Combination Therapy of Severe Aplastic Anemia
For Condition: Aplastic Anemia
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study will test the safety and effectiveness of a combination of three drugs in treating severe aplastic anemia and preventing its recurrence. Two drugs used in this trial-ATG and cyclosporine-are standard combination therapy for aplastic anemia. This study will try to improve this therapy in three ways: 1) by altering the drug regimen to allow the drugs to work better; 2) by reducing the risk of kidney damage; and 3) by adding a third drug-mycophenolate mofetil-to try to prevent disease relapse. Patients with severe aplastic anemia who do not have a suitable bone marrow donor or who decline bone marrow transplantation may participate in this study. Patients will have a skin test for ATG allergy, chest X-ray, blood test, and bone marrow aspiration before treatment begins. ATG will then be started, infused through a vein continuously for 4 days. Ten days after ATG is stopped, cyclosporine treatment will begin, taken twice a day by mouth in either liquid or capsule form and will continue for 6 months. Also, in the first 2 weeks of treatment, patients will be given a full dose of corticosteroid (prednisone) to prevent serum sickness that could develop as a side effect of ATG therapy. The dosage will be decreased after that. Mycophenolate will be started at the same time as ATG, in two daily doses by mouth, and will continue for 18 months. Patients will be hospitalized at the beginning of the study. During this time, blood will be drawn at 3-week intervals and a bone marrow examination will be repeated 3 months after treatment has begun. Additional tests, including X-rays may be required. After hospital discharge, patients will be followed on an outpatient basis at 3-month intervals. The patients' own physician will perform blood tests weekly and kidney and liver function tests every 2 weeks during cyclosporine therapy. Transfusions may be required initially.
Details: Severe acquired aplastic anemia (SAA) has a poor prognosis if untreated. Bone marrow transplantation is available to only a minority of patients due to lack of a matched sibling donor, advanced age of the patient, or cost. Clinical studies at NIH and elsewhere have demonstrated excellent response rates and improved survival with immunosuppressive treatments. Laboratory data implicate underlying cytotoxic T-lymphocyte-mediated suppression of hematopoiesis as the likely proximal cause of disease in most patients. In earlier clinical protocols we treated SAA with cyclosporine A (CSA) (86-H-0007), antithymocyte globulin (ATG) (87-H-0124), and combined ATG and CSA (90-H-0146). While intensive immunosuppression is most effective, relapse is common and some patients also develop second hematologic complications like myelodysplasia. In this protocol, we modify our regimen by delaying the introduction of cyclosporine to promote ATG tolerizing effects and adding mycophenolate mofetil (MMF), a new agent that, like ATG may be relatively specific for activated lymphocytes, in an effort to reduce the high relapse rate.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Only patients with SAA will be admitted, defined as: Bone marrow cellularity less than 30%. At least two of the following blood count findings: absolute granulocyte count less than 500/mm(3); platelet count less than 20,000/mm(3); reticulocyte count less than 60,000/mm(3). Age greater than or equal to 1 years. Weight greater than 12 kg. EXCLUSION CRITERIA: Serum creatinine greater than 2 mg/dl or estimated creatinine clearance less than 40 ml/min. Underlying carcinoma, recent history of radiation or chemotherapy. Current pregnancy or unwillingness to be treated with oral contraceptives. Inability to comprehend the investigational nature of the study. Moribund status or concurrent hepatic, renal, cardiac, neurologic, or metabolic disease of such severity that death within 7 to 10 days is likely. Evidence of other etiology than AA for bone marrow failure, including positive clastogenic stress cytogenetic assay for Fanconi anemia and marrow chromosome abnormalities typical of myelodysplasia.
Total Enrollment: 100
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 000032; 00-H-0032
Study Start Date: December 1, 1999
Record last reviewed: December 5, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001964
Other Aplastic Anemia Studies:
1. Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Transplantation for Patients with Hematologic Malignancies or Bone Marrow Failure States
2. Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
3. Improving Immunosuppressive Treatment for Patients with Severe Aplastic Anemia
4. Phase III Randomized Study of Cyclophosphamide with or without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients with Aplastic Anemia
5. Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
Related Studies:
Other Aplastic Anemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Combination Therapy of Severe Aplastic Anemia
|
|
|
|
|
|
|
|
